Keya Medical Announces Strategic Partnerships to Expand Coverage in the US

by | Jul 8, 2025 | Press

Transforming Healthcare with AI-Powered Innovations

Keya Medical, a prominent innovator in advanced medical imaging and artificial intelligence solutions, is set to enhance its presence in the United States through a series of strategic partnerships. This initiative represents a groundbreaking step in the company’s mission to make its flagship CT-based FFR analysis tool, DeepVessel FFR (DVFFR), widely available to healthcare providers and patients across the nation.

Key Partnerships

Keya Medical has partnered with influential organizations to facilitate its expansion:

Calantic™ Digital Solutions is an orchestrated suite of cloud-based clinical and operational Radiology AI applications.

A renowned service provider with an extensive portfolio for advanced and AI-enabled 3D CT & MR image post-processing for cardiac, neuro, and vascular cases.

CARPL.ai is one of the world’s largest radiology AI marketplaces, offering over 175+ applications from 75+ AI vendors. With its unified user interface, single data channel, and streamlined procurement system, CARPL.ai empowers radiologists to easily access, assess, and integrate AI solutions into clinical practice.

Nathan Qin joins Keya’s advisory board as executive advisor. In this role, he will spearhead Keya’s global expansion initiatives by navigating complex regulatory environments and driving high-value commercial partnerships across key international markets.

Impact on the US Healthcare Landscape

Through these partnerships, Keya Medical aims to expand access to its FDA-approved DeepVessel FFR, providing non-invasive solutions for coronary artery assessments. The product is uniquely positioned to improve healthcare outcomes by offering precise diagnostics without the need for invasive procedures.

DV FFR Features and Benefits

DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, NMPA-Cleared, HSA-Certified.

Precise

Achieves diagnostic accuracy using invasive FFR as the reference standard, with a low rejection rate.

Comprehensive

Maps FFR at every point along the coronary tree, providing detailed 3D models and PDF reports.

Value-Based

Empowers physicians with autonomy in decision-making and prioritizes their expertise. Pricing is aligned to reimbursement.

Streamlined

Requires no CT scanner certification, software maintenance, or additional staff training.

Learn more about DEEPVESSEL FFR

We are actively looking for clinical partners in the United States and EMEA.

Send us a message